title: Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness.
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam2Department of Public Health, Erasmus University Medical Center, Rotterdam.
authors.forename: Eric C T
authors.initials: EC
authors.lastname: Geijteman
authors.affiliation: Department of Epidemiology, Erasmus University Medical Center, Rotterdam.
authors.forename: Henning
authors.initials: H
authors.lastname: Tiemeier
authors.affiliation: Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam.
authors.forename: Teun
authors.initials: T
authors.lastname: van Gelder
mesh_terms: D002318:Cardiovascular Diseases; D003072:Cognition Disorders; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D009369:Neoplasms; D010166:Palliative Care / Q000379:methods*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors